Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Researchers at the Buck Institute have identified and categorized thousands of protein interactions involving huntingtin, the protein responsible for Huntington's disease (HD). To use an analogy of a human social network, the identified proteins are like "friends" and "friends of friends" of the HD protein.

28 Feb 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Ellex Medical Lasers Limited, a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that it has secured a CE Mark (Conformité Européenne) for its proprietary Retinal Rejuvenation Therapy (2RT) laser treatment of early Age-Related Macular Degeneration (AMD).

24 Feb 2014

Study reveals that color vision abnormalities increase with age

Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry.

24 Feb 2014

Study indicates relationship between multivitamin supplement use and cataract risk in men

Long-term daily multivitamin supplement use may lower cataract risk in men, according to a study of nearly 15,000 male physicians published this month in Ophthalmology, the journal of the American Academy of Ophthalmology

21 Feb 2014

Newly developed compound may allow blind see light

Progressive degeneration of photoreceptors-the rods and cones of the eyes-causes blinding diseases such as retinitis pigmentosa and age-related macular degeneration. While there are currently no available treatments to reverse this degeneration, a newly developed compound allows other cells in the eye to act like photoreceptors. As described in a study appearing in the February 19 issue of the Cell Press journal Neuron, the compound may be a potential drug candidate for treating patients suffering from degenerative retinal disorders.

20 Feb 2014

Perceptual learning can improve vision and on field performance in baseball

With a little practice on a computer or iPad-25 minutes a day, 4 days a week, for 2 months-our brains can learn to see better, according to a study of University of California, Riverside baseball players reported in the Cell Press journal Current Biology on February 17.

18 Feb 2014

Pitt’s CMI funds 6 research groups for Early Stage Medical Technology Research and Development

The University of Pittsburgh's Center for Medical Innovation (CMI) awarded a total of $82,000 to six research groups through its 2013 Round-2 Pilot Funding Program for Early Stage Medical Technology Research and Development.

11 Feb 2014

Nutrition and exercise have significant impact on one's vision

With the New Year comes many resolutions, including resolving to exercise more and eat better. While many individuals understand that nutrition and exercise play an important role in helping to prevent diabetes, obesity, and cardiovascular disorders, not many may be aware that these two elements have a significant impact on one's vision as well. Dr. Sandy T. Feldman, a renowned ophthalmologist and corneal expert at Clearview Eye & Laser Center in San Diego, advises patients to examine their physical fitness and eating habits in order to achieve optimum vision.

11 Feb 2014

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Moderate aerobic exercise helps to preserve the structure and function of nerve cells in the retina after damage, according to an animal study appearing February 12 in The Journal of Neuroscience. The findings suggest exercise may be able to slow the progression of retinal degenerative diseases.

9 Feb 2014

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BioTime, Inc. and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

28 Jan 2014

BioTime subsidiary releases version 1.5 of LifeMap Discovery

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of LifeMap Discovery version 1.5. LifeMap Discovery is a state-of-the-art roadmap of embryonic development and stem cell biology.

18 Jan 2014

New gene therapy restores some sight in people born with inherited form of blindness

A new gene therapy has restored some sight in people born with an inherited, progressive form of blindness. The technique replaces a defective gene in the eye with a normal working copy of the gene using a single injection.

16 Jan 2014

Study finds nearly 70% of U.S. adults experience digital eye strain on using digital devices

A report released today at the 2014 Consumer Electronics Show by The Vision Council finds that nearly 70 percent of U.S. adults experience digital eye strain while on digital devices – including computers, tablets and smartphones.

9 Jan 2014

Melanocyte-secreted fibromodulin promotes angiogenic microenvironment

The decreased vision loss that accompanies age-related macular degeneration (AMD) is associated with abnormal blood vessel growth in the eye. Frequencies of AMD development are different among racial backgrounds, with occurrence of AMD highest among individuals of mixed European decent.

22 Dec 2013

Scientists develop new potential cure for rare eye disease

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

22 Dec 2013

New optical device puts the power to detect retinal disease in the palm of a hand

A new optical device puts the power to detect eye disease in the palm of a hand. The tool-about the size of a hand-held video camera-scans a patient's entire retina in seconds and could aid primary care physicians in the early detection of a host of retinal diseases including diabetic retinopathy, glaucoma and macular degeneration.

22 Dec 2013

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Study reveals that color vision abnormalities increase with age

Study indicates relationship between multivitamin supplement use and cataract risk in men

Newly developed compound may allow blind see light

Perceptual learning can improve vision and on field performance in baseball

Pitt’s CMI funds 6 research groups for Early Stage Medical Technology Research and Development

Nutrition and exercise have significant impact on one's vision

Moderate aerobic exercise helps preserve nerve cells in retina after damage

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BioTime subsidiary releases version 1.5 of LifeMap Discovery

New gene therapy restores some sight in people born with inherited form of blindness

Study finds nearly 70% of U.S. adults experience digital eye strain on using digital devices

Melanocyte-secreted fibromodulin promotes angiogenic microenvironment

Scientists develop new potential cure for rare eye disease

New optical device puts the power to detect retinal disease in the palm of a hand

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in